"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 3 | 2 | 5 |
| 2017 | 21 | 17 | 38 |
| 2018 | 14 | 18 | 32 |
| 2019 | 7 | 7 | 14 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. Biochem J. 2021 07 16; 478(13):2517-2531.
-
In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease. ChemMedChem. 2021 08 05; 16(15):2339-2344.
-
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021 07 01; 12(1):4068.
-
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2021 06 23; 78(13):1184-1194.
-
Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Sci Rep. 2021 05 27; 11(1):11130.
-
Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow. Mol Divers. 2022 Feb; 26(1):389-407.
-
Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation. Mol Divers. 2022 Feb; 26(1):309-329.
-
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat Commun. 2021 03 25; 12(1):1876.
-
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Mar 16; 22(1):209.